Diabetes and well-being is the theme for World Diabetes Day 2024-26.

On November 14th, we join the global community in recognizing World Diabetes Day, a day dedicated to raising awareness about the impact of diabetes worldwide. Led by the International Diabetes Federation (IDF), World Diabetes Day emphasizes the importance of education, early diagnosis, and access to effective treatments for over 500 million people worldwide currently living with diabetes.

At Tiefenbacher Group, we are committed to making a difference by providing more affordable, more available, and better therapies to improve the life of people affected by diabetes. Our portfolio includes pharmaceuticals like Vildagliptin, which is available as monotherapy and in combination with Metformin. Vildagliptin is a DPP-4 inhibitor, which helps to improve blood sugar control in adults with type 2 diabetes by enhancing the body’s natural regulation of insulin and glucose.

On World Diabetes Day, we stand with patients, their relatives, and healthcare providers in the fight against diabetes. Together, we strive for a future where everyone has access to the care and resources they need.

Contact us:

In case of inquiries please reach out to licensing@tiefenbacher.com

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com